VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 83.79% for the 12-month period ending 2021-03-31, per its 10-K filed 2021-06-29.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2021-06-29
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 83.79%, a 3.68% decline from fiscal 2020.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 86.99%, a 9.93% decline from fiscal 2019.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 96.58%, a 6.84% increase from fiscal 2018.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2018 was 90.40%, a 8.97% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|
| 2021-03-31 | 83.79% 10-K · filed 2021-06-29 |
| 2020-03-31 | 86.99% 10-K · filed 2021-06-29 |
| 2019-03-31 | 96.58% 10-K · filed 2020-06-29 |
| 2018-03-31 | 90.40% 10-K · filed 2019-06-25 |
| 2017-03-31 | 82.96% 10-K · filed 2018-06-26 |
| 2016-03-31 | 93.27% 10-K · filed 2017-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |